Randomized trial demonstrates antiviral activity of novel compounds in SARS-CoV-2, highlighting potential treatments.
A combination of 1,2,3-triazole and pyrimidin-2-thione moieties in the same matrix was achieved via a multi-step synthetic pathway. The target novel 1,2,3-triaozle-pyrimidin-2-thione derivatives 4a-f were obtained via the condensation reaction of the synthesized chalcones 3a-f with thiourea in the presence of sodium hydroxide. Compounds 4a-f were characterized by FT-IR, 1H-NMR and 13C-NMR spectroscopies. The biological activity of the synthesized compounds 4a-f and their precursors 3a-f as antiviral was studied by molecular docking analysis against two selected enzymes (7dpp and 8cx9) which play an essential role in SARS-CoV-2 replication. Practically, the results revealed that all the synthesized compounds 4a-f and their precursors 3a-f displayed a promising binding affinity into the active site pocket through the target proteins compared to Remdesivir, X77 and N3 as standard antiviral drugs.
No takes yet. Share an insight, caveat, or question.
KOZAN et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: